ABVC BioPharma, Inc. (ABVC)
| Market Cap | 35.13M +73.0% |
| Revenue (ttm) | n/a |
| Net Income | -8.63M |
| EPS | -0.38 |
| Shares Out | 25.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 231,908 |
| Open | 1.290 |
| Previous Close | 1.290 |
| Day's Range | 1.260 - 1.460 |
| 52-Week Range | 0.880 - 5.480 |
| Beta | 0.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 18, 2026 |
About ABVC
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ... [Read more]
Financial Performance
Financial StatementsNews
ABVC BioPharma Quarterly report: Q1 2026
ABVC BioPharma has published its Q1 2026 quarterly earnings report on May 18, 2026.
ABVC BioPharma Proxy statement: Proxy Filing
ABVC BioPharma filed a proxy statement on March 5, 2026, providing details for shareholder voting and corporate governance matters.
ABVC BioPharma Annual report: Q4 2025
ABVC BioPharma has published its Q4 2025 annual report on March 3, 2026.
ABVC BioPharma Proxy statement: Proxy Filing
ABVC BioPharma filed a proxy statement on February 5, 2026, providing details for shareholder voting and corporate governance matters.
ABVC BioPharma Earnings release: Q3 2025
ABVC BioPharma released its Q3 2025 earnings on November 3, 2025, summarizing the period's financial results.
ABVC BioPharma Quarterly report: Q3 2025
ABVC BioPharma has published its Q3 2025 quarterly earnings report on November 3, 2025.
ABVC BioPharma Earnings release: Q2 2025
ABVC BioPharma released its Q2 2025 earnings on August 13, 2025, summarizing the period's financial results.
ABVC BioPharma Quarterly report: Q2 2025
ABVC BioPharma has published its Q2 2025 quarterly earnings report on August 13, 2025.
Sixteen new option listings on July 23rd
New option listings for July 23rd include ABVC Biopharma Inc (ABVC), Astex Pharmaceuticals Inc (ASTX), Bitmine Immersion Technologies Inc (BMNR), BTCS Inc (BTCS), Columbus Circle Capital I Corp (CCCM)...
ABVC BioPharma files $100M mixed securities shelf
16:04 EDT ABVC BioPharma (ABVC) files $100M mixed securities shelf
ABVC BioPharma Registration statement: Registration Filing
ABVC BioPharma filed a registration statement on May 22, 2025, providing details about a securities offering with the SEC.
ABVC BioPharma Proxy statement: Proxy Filing
ABVC BioPharma filed a proxy statement on May 16, 2025, providing details for shareholder voting and corporate governance matters.
ABVC BioPharma Quarterly report: Q1 2025
ABVC BioPharma has published its Q1 2025 quarterly earnings report on April 29, 2025.
ABVC BioPharma Proxy statement: Proxy Filing
ABVC BioPharma filed a proxy statement on April 25, 2025, providing details for shareholder voting and corporate governance matters.
ABVC BioPharma Earnings release: Q4 2024
ABVC BioPharma released its Q4 2024 earnings on April 15, 2025, summarizing the period's financial results.
ABVC BioPharma Quarterly report: Q4 2024
ABVC BioPharma has published its Q4 2024 quarterly earnings report on April 15, 2025.
ABVC BioPharma Annual report: Q4 2024
ABVC BioPharma has published its Q4 2024 annual report on April 15, 2025.
ABVC BioPharma believes ABV-1504 can fill void in market after Prozac
ABVC BioPharma (ABVC) announced in response to the discontinuation of Prozac due to increasing concerns around side effects, ABVC believes its ABV-1504, which has the API, “Radix Polygala”, known as…
ABVC BioPharma receives $200,000 cash payment from OncoX
ABVC BioPharma (ABVC) announced the receipt of a $200,000 cash payment from OncoX BioPharma as part of its strategic licensing agreement for certain oncology-related products; this payment marks the f...
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervou...
ABVC BioPharma reports Q3 EPS (2c) vs (82c) last year
Reports Q3 revenue $389,276 vs $15,884 last year. Improved Cash Position: The Company’s cash and cash equivalents reached $137,344 as of September 30, 2024, up from $60,155 at the end…
ABVC BioPharma Quarterly report: Q3 2024
ABVC BioPharma has published its Q3 2024 quarterly earnings report on November 14, 2024.
ABVC BioPharma Earnings release: Q3 2024
ABVC BioPharma released its Q3 2024 earnings on November 14, 2024, summarizing the period's financial results.
ABVC BioPharma receives $50,000 in incremental licensing fees
ABVC BioPharma (ABVC) announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees…
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervo...